{"id":"apidra-insulin-glulisine","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Insulin glulisine is a recombinant human insulin analog with amino acid substitutions that accelerate its absorption and onset of action compared to regular human insulin. It binds to the insulin receptor, activating intracellular signaling that increases glucose transport into cells and promotes glycogen synthesis while inhibiting gluconeogenesis. This results in rapid lowering of postprandial and fasting blood glucose in patients with diabetes.","oneSentence":"Insulin glulisine is a rapid-acting insulin analog that binds to insulin receptors on muscle and fat cells to promote glucose uptake and lower blood glucose levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:30:02.635Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT04124302","phase":"PHASE4","title":"The Impact of Two Different Insulin Dose Calculation on Postprandial Glycemia After Mixed Meal.","status":"COMPLETED","sponsor":"Medical University of Warsaw","startDate":"2019-10-01","conditions":"Diabetes Mellitus, Type 1","enrollment":76},{"nctId":"NCT07070752","phase":"PHASE3","title":"Evaluation of Insulin Glulisine (GP40321) Compared to Insulin Glulisine (Apidra® SoloStar®) in Type 1 Diabetes Mellitus Patients","status":"COMPLETED","sponsor":"Geropharm","startDate":"2023-04-14","conditions":"Type 1 Diabetes Mellitis","enrollment":224},{"nctId":"NCT04974528","phase":"PHASE3","title":"Afrezza® INHALE-1 Study in Pediatrics","status":"COMPLETED","sponsor":"Mannkind Corporation","startDate":"2021-09-29","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":319},{"nctId":"NCT05036876","phase":"NA","title":"Degludec Glargine U300 Hospital Study","status":"COMPLETED","sponsor":"Medanta, The Medicity, India","startDate":"2021-10-10","conditions":"Type 2 Diabetes","enrollment":220},{"nctId":"NCT02914886","phase":"PHASE4","title":"Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS)","status":"COMPLETED","sponsor":"Kinderkrankenhaus auf der Bult","startDate":"2016-09","conditions":"Type 1 Diabetes, Lipoatrophy","enrollment":14},{"nctId":"NCT00708981","phase":"NA","title":"Combined Diabetes-Renal Multifactorial Intervention In Patients With Advanced Diabetic Nephropathy (ADN)","status":"COMPLETED","sponsor":"Cook County Health","startDate":"2007-05","conditions":"Diabetic Nephropathy","enrollment":120},{"nctId":"NCT02871089","phase":"NA","title":"Closed Loop From Onset in Type 1 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Cambridge","startDate":"2017-01","conditions":"Diabetes Mellitus, Type 1 Diabetes","enrollment":96},{"nctId":"NCT02048189","phase":"PHASE4","title":"Treatment With Continuous Sub-cutaneous Insulin Infusion Via a Portable Pump Versus Discontinuous Insulin Infusion Via Multiple-injections in Type 2 Diabetes","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2012-03-08","conditions":"Patient With Type 2 Diabetes Treated With Insulin Using a Baseline/Bolus Strategy","enrollment":14},{"nctId":"NCT02518945","phase":"PHASE3","title":"Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2015-08","conditions":"Type 1 Diabetes Mellitus","enrollment":26},{"nctId":"NCT04019821","phase":"PHASE4","title":"Super-Bolus: Effects on Postprandial Glycemia After High Glycemic Index Meal","status":"COMPLETED","sponsor":"Medical University of Warsaw","startDate":"2020-01-01","conditions":"Diabetes Mellitus, Type 1","enrollment":72},{"nctId":"NCT00913497","phase":"PHASE4","title":"The Effect of Insulin Glulisine Compared With Insulin Aspart on Breakfast Post Prandial Glucose Levels in Prepubertal Children","status":"COMPLETED","sponsor":"Corewell Health West","startDate":"2009-06","conditions":"Type 1 Diabetes Mellitus","enrollment":16},{"nctId":"NCT03359837","phase":"PHASE4","title":"Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-01-20","conditions":"Type 2 Diabetes Mellitus","enrollment":384},{"nctId":"NCT03529123","phase":"PHASE3","title":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-06-19","conditions":"Type 2 Diabetes Mellitus","enrollment":247},{"nctId":"NCT02910518","phase":"PHASE1","title":"A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2017-02-17","conditions":"Type1 Diabetes Mellitus","enrollment":44},{"nctId":"NCT03260868","phase":"PHASE4","title":"Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy)","status":"TERMINATED","sponsor":"Sanofi","startDate":"2017-09-19","conditions":"Type 1 Diabetes Mellitus","enrollment":15},{"nctId":"NCT02688933","phase":"PHASE4","title":"A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-05-05","conditions":"Type 1 Diabetes Mellitus","enrollment":638},{"nctId":"NCT03328845","phase":"PHASE4","title":"Impact on the Oxidative Stress of the Different Analogues of Insulin in People With Type 1 Diabetes. (Ineox Study)","status":"COMPLETED","sponsor":"Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud","startDate":"2017-01-20","conditions":"Type 1 Diabetes Mellitus","enrollment":300},{"nctId":"NCT04965051","phase":"NA","title":"Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T1DM","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2021-08","conditions":"Type 1 Diabetes Mellitus With Diabetic Gastroparesis, HbA1c, Time in Range","enrollment":40},{"nctId":"NCT03495908","phase":"NA","title":"Regular Insulin vs Rapid Insulin Delivered by V-Go","status":"COMPLETED","sponsor":"East Coast Institute for Research","startDate":"2018-04-09","conditions":"Type 2 Diabetes, Type 2 Diabetes Mellitus","enrollment":136},{"nctId":"NCT02846831","phase":"PHASE2","title":"Closed-loop Control of Glucose Levels (Artificial Pancreas) for 12 Days in Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"2019-01-24","conditions":"Type 1 Diabetes","enrollment":36},{"nctId":"NCT03013985","phase":"PHASE4","title":"Glargine U300 Hospital Trial","status":"COMPLETED","sponsor":"Emory University","startDate":"2017-05-17","conditions":"Type 2 Diabetes","enrollment":247},{"nctId":"NCT02503501","phase":"PHASE2","title":"Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease","status":"TERMINATED","sponsor":"HealthPartners Institute","startDate":"2015-09-28","conditions":"Mild Cognitive Impairment, Alzheimer's Disease (AD)","enrollment":49},{"nctId":"NCT01684943","phase":"NA","title":"Selecting Insulin Analogs for Closed-Loop Control Using Multiplex Pharmacokinetic Profiling","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2010-07","conditions":"Type 1 Diabetes","enrollment":33},{"nctId":"NCT02432716","phase":"PHASE1","title":"Investigation of the Safety of Intranasal Glulisine in Down Syndrome","status":"COMPLETED","sponsor":"HealthPartners Institute","startDate":"2015-04","conditions":"Down Syndrome","enrollment":12},{"nctId":"NCT02987751","phase":"PHASE4","title":"A Study on Comparison of Glargine Plus Glulisine With Premixed Insulin in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals","startDate":"2016-12-29","conditions":"Type2 Diabetes","enrollment":200},{"nctId":"NCT02846857","phase":"PHASE2","title":"Closed-loop Control of Glucose Levels (Artificial Pancreas) for 15 Weeks in Adolescents and Adults With Type 1 Diabetes","status":"WITHDRAWN","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"","conditions":"Type 1 Diabetes","enrollment":""},{"nctId":"NCT01194245","phase":"PHASE2","title":"Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2010-08","conditions":"Diabetes Mellitus, Type 1","enrollment":135},{"nctId":"NCT01855243","phase":"NA","title":"Comparison on Efficacy and Safety of Three Inpatient Insulin Therapy in Type2 DM","status":"COMPLETED","sponsor":"Cairo University","startDate":"2010-03","conditions":"Diabetes Mellitus (DM)","enrollment":63},{"nctId":"NCT01848990","phase":"PHASE4","title":"CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2013-03","conditions":"Type 1 Diabetes Mellitus","enrollment":456},{"nctId":"NCT00394524","phase":"NA","title":"Trial Between a Computer-Guided Insulin Infusion Protocol Versus a Standard Insulin Infusion Algorithm in Medical ICU","status":"COMPLETED","sponsor":"Emory University","startDate":"2006-06","conditions":"Diabetes or With New Hyperglycemia","enrollment":160},{"nctId":"NCT00979628","phase":"PHASE4","title":"Basal Bolus Versus Basal Insulin in Type 2 Diabetes Mellitus (T2DM)","status":"COMPLETED","sponsor":"Guillermo Umpierrez, MD","startDate":"2010-01","conditions":"Type 2 Diabetes, Hyperglycemia","enrollment":375},{"nctId":"NCT00590044","phase":"PHASE4","title":"Basal Insulin in the Management of Patients With Diabetic Ketoacidosis (DKA)","status":"COMPLETED","sponsor":"Emory University","startDate":"2007-12","conditions":"Diabetic Ketoacidosis","enrollment":74},{"nctId":"NCT01792830","phase":"PHASE3","title":"Efficacy and Safety of a Glargine-based Hospital Discharge Algorithm in Coronary Artery Bypass Graft (CABG) Patients","status":"COMPLETED","sponsor":"Emory University","startDate":"2012-10","conditions":"Poor Glycemic Control","enrollment":175},{"nctId":"NCT01662921","phase":"PHASE2","title":"Comparator Trial Using Insulin Glulisine vs. Insulin Lispro for Treatment of Gestational Diabetes","status":"COMPLETED","sponsor":"Sansum Diabetes Research Institute","startDate":"2013-04","conditions":"Diabetes During Pregnancy","enrollment":17},{"nctId":"NCT01594060","phase":"PHASE4","title":"Basal Bolus vs. Sliding Scale for Treatment of Diabetic Patients in Medical Wards","status":"COMPLETED","sponsor":"HaEmek Medical Center, Israel","startDate":"2012-06","conditions":"Diabetes Mellitus Type 2","enrollment":36},{"nctId":"NCT02276859","phase":"PHASE4","title":"Normal Versus Dual Wave Insulin Bolus for High-protein Food","status":"COMPLETED","sponsor":"Medical University of Warsaw","startDate":"2014-10","conditions":"Type 1 Diabetes","enrollment":70},{"nctId":"NCT02488616","phase":"PHASE2","title":"Closed-loop Control of Glucose Levels (Artificial Pancreas) for 5 Days in Adults With Type 1 Diabetes","status":"WITHDRAWN","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"2018-03","conditions":"Type 1 Diabetes","enrollment":""},{"nctId":"NCT02490098","phase":"PHASE2","title":"Closed-loop Control of Postprandial Glucose Levels in Children and Adults With Type 1 Diabetes","status":"WITHDRAWN","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"2018-01","conditions":"Type 1 Diabetes","enrollment":""},{"nctId":"NCT03051243","phase":"PHASE3","title":"Safety and Efficiency of Linagliptin (Trajenta) in the Setting of Internal Medicine Department","status":"UNKNOWN","sponsor":"Rabin Medical Center","startDate":"2017-10-01","conditions":"DM2","enrollment":60},{"nctId":"NCT02798250","phase":"PHASE2","title":"Safety of Overestimation of a Meal Insulin Bolus in the Context of Dual-hormone Closed-loop Operation - Part 2","status":"COMPLETED","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"2016-06","conditions":"Type 1 Diabetes","enrollment":11},{"nctId":"NCT03112538","phase":"PHASE4","title":"Improving Glycaemic Control in Malaysian Patients With Type 2 Diabetes Mellitus With Insulin Pump Therapy","status":"UNKNOWN","sponsor":"Clinical Research Centre, Malaysia","startDate":"2016-01","conditions":"Type 2 Diabetes Mellitus","enrollment":118},{"nctId":"NCT00911625","phase":"PHASE4","title":"Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency","status":"COMPLETED","sponsor":"Loyola University","startDate":"2009-01-21","conditions":"Type 2 Diabetes, Renal Insufficiency","enrollment":114},{"nctId":"NCT00824668","phase":"PHASE1","title":"Comparison of Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30 and Insulin Glargine and Insulin Glulisine Therapy in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-08","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":24},{"nctId":"NCT01768559","phase":"PHASE3","title":"Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-01","conditions":"Type 2 Diabetes","enrollment":894},{"nctId":"NCT02685449","phase":"PHASE4","title":"Insulin Requirement for Pure-protein Meal in Children With Type 1 Diabetes on Insulin Pumps.","status":"UNKNOWN","sponsor":"Medical University of Warsaw","startDate":"2016-02","conditions":"Diabetes type1","enrollment":70},{"nctId":"NCT01234597","phase":"PHASE4","title":"Evaluation of the Prandial Treatment Adjustment Effect Via Continuous Glucose Monitoring on Type 2 Diabetes Mellitus (DM) Patients Uncontrolled With a Basal Insulin or Premix Once a Day","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-12","conditions":"Diabetes Mellitus, Type 2","enrollment":219},{"nctId":"NCT02626936","phase":"PHASE2","title":"Safety of Overestimation of a Meal Insulin Bolus in the Context of Dual-hormone Closed-loop Operation","status":"COMPLETED","sponsor":"Institut de Recherches Cliniques de Montreal","startDate":"2016-01","conditions":"Type 1 Diabetes","enrollment":10},{"nctId":"NCT00115570","phase":"PHASE3","title":"Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-04","conditions":"Diabetes Mellitus, Insulin-Dependent","enrollment":572},{"nctId":"NCT02276196","phase":"PHASE4","title":"Effect of LIXIsenatide on the Renal System","status":"COMPLETED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2014-09","conditions":"Diabetic Kidney Disease, Diabetic Nephropathy, Diabetes Mellitus","enrollment":40},{"nctId":"NCT01436045","phase":"PHASE2","title":"Safety and Effectiveness Study of Intranasal Insulin Glulisine on Cognitive and Memory in Mild-Mod AD Patients.","status":"COMPLETED","sponsor":"HealthPartners Institute","startDate":"2011-09","conditions":"Alzheimer's Disease","enrollment":12},{"nctId":"NCT00582309","phase":"NA","title":"Comparative Trial Between 3 Types of Insulin Infusion Protocols","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"2007-08","conditions":"Hyperglycemia","enrollment":151},{"nctId":"NCT00467649","phase":"PHASE4","title":"A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-05","conditions":"Type 2 Diabetes Mellitus","enrollment":112},{"nctId":"NCT02333851","phase":"PHASE4","title":"Basal-bolus and Premixed Insulin Regimens in Hospitalized Patients With Type 2 Diabetes (PININ Study)","status":"TERMINATED","sponsor":"Hospital Universitario Central de Asturias","startDate":"2013-06","conditions":"Type 2 Diabetes Mellitus","enrollment":72},{"nctId":"NCT01131052","phase":"PHASE4","title":"Diabetes in the Elderly: Prospective Study","status":"COMPLETED","sponsor":"Guillermo Umpierrez","startDate":"2011-03","conditions":"Diabetes, Hyperglycemia","enrollment":150},{"nctId":"NCT00927524","phase":"NA","title":"Insulin Exposure and Glucose Response to Meals in Type 1 Diabetic Subjects Administered Two Different Insulin Regimens Compared to the Endogenous Insulin Exposure and Glucose Response to Meals In Healthy Adult Controls","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2005-04","conditions":"Type 1 Diabetes","enrollment":24},{"nctId":"NCT02278913","phase":"PHASE4","title":"Basal Bolus Versus Human Insulin in Hospitalized Patients With Diabetes in Paraguay","status":"COMPLETED","sponsor":"Universidad Nacional de Asunción","startDate":"2009-04","conditions":"Hyperglycemia, Diabetes","enrollment":134},{"nctId":"NCT01678235","phase":"PHASE4","title":"Insulin Glulisine and Aspart in Postprandial Glycemic Control After High-GI Meal in Children With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Medical University of Warsaw","startDate":"2011-09","conditions":"Type 1 Diabetes Mellitus","enrollment":64},{"nctId":"NCT01194258","phase":"PHASE2","title":"Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2010-08","conditions":"Diabetes Mellitus, Type II","enrollment":132},{"nctId":"NCT00528918","phase":"NA","title":"Comparison of Apidra to Regular Insulin in Hospitalized Patients","status":"COMPLETED","sponsor":"Carl T. Hayden VA Medical Center","startDate":"2007-06","conditions":"Diabetes Mellitus, Type II","enrollment":300},{"nctId":"NCT00979875","phase":"PHASE1","title":"A Pharmacokinetic and Glucodynamic Study of Subcutaneously Administered Insulin Analogs With rHuPH20 Compared to Insulin Analogs Alone","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2009-09","conditions":"Healthy","enrollment":14},{"nctId":"NCT01087567","phase":"PHASE4","title":"INSPIRE Diabetes Study: Basal Bolus Insulin as Primary Treatment of Type 2 Diabetes","status":"COMPLETED","sponsor":"Ohio University","startDate":"2010-07","conditions":"Type 2 Diabetes","enrollment":23},{"nctId":"NCT01204593","phase":"PHASE4","title":"baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-11","conditions":"Diabetes Mellitus, Type 1","enrollment":206},{"nctId":"NCT00596687","phase":"PHASE4","title":"Basal Bolus Insulin Versus SSRI in Type 2 Diabetes Undergoing General Surgery","status":"COMPLETED","sponsor":"Emory University","startDate":"2007-12","conditions":"Type 2 Diabetes, Inpatient Hyperglycemia","enrollment":234},{"nctId":"NCT00394407","phase":"PHASE4","title":"Basal/Bolus Versus Sliding Scale Insulin In Hospitalized Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Emory University","startDate":"2005-09","conditions":"Diabetes, Hyperglycemia","enrollment":130},{"nctId":"NCT01122979","phase":"PHASE4","title":"Evaluation of the Safety and Efficacy of Insulin Glargine + Glulisine or Insulin Regular + NPH Insulin (Isophane Insulin) Use in Type 2 Diabetes Mellitus Patients With Moderate Renal Failure.","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-07","conditions":"Diabetes Mellitus, Type 2","enrollment":72},{"nctId":"NCT00474838","phase":"PHASE4","title":"Study To Evaluate Beta Cell Function and Glycemic Outcome by Intensive Insulin Therapy","status":"COMPLETED","sponsor":"Kyunghee University Medical Center","startDate":"2007-04","conditions":"Type 2 Diabetes Mellitus, Pancreatic Beta Cell Function, Glucotoxicity","enrollment":112},{"nctId":"NCT01621776","phase":"NA","title":"Effect of Apidra Compared to Humalog in Decreasing Post-Prandial Hyperglycemia","status":"COMPLETED","sponsor":"University of Florida","startDate":"2011-06","conditions":"Type 1 Diabetes","enrollment":107},{"nctId":"NCT00943709","phase":"PHASE3","title":"Intensive Glycemic Control on Infectious Morbidity In Patients With Acute Leukemia","status":"WITHDRAWN","sponsor":"University of Medicine and Dentistry of New Jersey","startDate":"2009-05","conditions":"Hyperglycemia, Leukemia","enrollment":""},{"nctId":"NCT01212913","phase":"PHASE4","title":"Comparison of Insulin Glargine/Insulin Glulisine Regimen to Insulin Aspart/Insulin Aspart Protamine 30/70 in Type 2 Diabetes Mellitus Patients (T2DM)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-08","conditions":"Diabetes Mellitus, Type 2","enrollment":161},{"nctId":"NCT01889914","phase":"PHASE4","title":"TReatment by Insulin Continuous Infusion in Type 2 DIAbetes","status":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2012-01","conditions":"Diabetes","enrollment":60},{"nctId":"NCT01079364","phase":"PHASE4","title":"Better Acceptance of Single Injection Apidra Added to Once Daily Lantus Versus Twice Daily Premixed Insulin in Real Life Use Setting","status":"TERMINATED","sponsor":"Sanofi","startDate":"2010-01","conditions":"Diabetes Mellitus, Type 2","enrollment":52},{"nctId":"NCT01121835","phase":"PHASE4","title":"Insulins Glargine and gluLisine strAtegy Versus Premixed Insulin strAteGy: a cOmparative Study","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-02","conditions":"Diabetes Mellitus, Type 2","enrollment":934},{"nctId":"NCT00965549","phase":"PHASE4","title":"Comparison of a Basal Plus One Insulin Regimen With a Biphasic Insulin Regimen in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-07","conditions":"Diabetes Mellitus, Type 2","enrollment":463},{"nctId":"NCT01202474","phase":"PHASE4","title":"Apidra Children & Adolescents Study","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-05","conditions":"Diabetes Mellitus, Type 1","enrollment":100},{"nctId":"NCT01203111","phase":"PHASE4","title":"Intensive Insulin Glulisine Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin and Oral Glucose-lowering Drugs","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-12","conditions":"Diabetes Mellitus, Type 2","enrollment":207},{"nctId":"NCT00964574","phase":"PHASE4","title":"Test of the Efficacy and Safety of Insulin Glulisine Injected Subcutaneously in Patients With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-07","conditions":"Diabetes Mellitus, Type 1","enrollment":68},{"nctId":"NCT00925977","phase":"NA","title":"Treatment Satisfaction of Insulin Glargine Plus Insulin Apidra Compared With NPH Insulin Plus Insulin Apidra in Recently Diagnosed Type 1 Diabetes Children and Adolescents","status":"TERMINATED","sponsor":"Rabin Medical Center","startDate":"2009-07","conditions":"Diabetes Type 1","enrollment":44},{"nctId":"NCT01081938","phase":"PHASE4","title":"Insulin Glargine for Diabetes Metabolism(DM)Type II Patients Under Enteral Nutrition","status":"TERMINATED","sponsor":"Sanofi","startDate":"2010-02","conditions":"Diabetes Mellitus, Type 2","enrollment":15},{"nctId":"NCT01013571","phase":"PHASE4","title":"Self Titration With Apidra to Reach Target Study (START)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-10","conditions":"Diabetes Mellitus, Type 2","enrollment":493},{"nctId":"NCT01417897","phase":"PHASE4","title":"Human Insulin Analogs: Evaluation of Inflammatory mRNA Expression of Macrophages and Endothelial Function of Short-acting Insulin - HERMES Pilot Study","status":"UNKNOWN","sponsor":"ikfe-CRO GmbH","startDate":"2011-09","conditions":"Type 2 Diabetes Mellitus","enrollment":12},{"nctId":"NCT01500850","phase":"PHASE4","title":"Establishing Cardiovascular Biomarkers to Define Preferred Lantus® Use","status":"UNKNOWN","sponsor":"ikfe-CRO GmbH","startDate":"2011-10","conditions":"Insulin-requiring Type 2 Diabetes Mellitus","enrollment":60},{"nctId":"NCT00360698","phase":"PHASE4","title":"Insulin Glulisine in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-07","conditions":"Diabetes Mellitus, Type 2","enrollment":106},{"nctId":"NCT00384085","phase":"PHASE4","title":"Insulin Glargine \"All to Target\" Trial","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-05","conditions":"Diabetes Mellitus, Type 2","enrollment":588},{"nctId":"NCT00670228","phase":"PHASE3","title":"Effect of Lantus and Apidra in Patients With Acute ST Elevation Myocardial Infarction","status":"TERMINATED","sponsor":"Sanofi","startDate":"2008-04","conditions":"AMI","enrollment":34},{"nctId":"NCT00283049","phase":"PHASE4","title":"Insulin Glargine Injection Treatment in Place of Thiazolidinedione (TZD), Sulfonylurea, or Metformin in Triple Agent Therapy for Type 2 Diabetes Mellitus (T2DM) Adult Subjects With Unsatisfactory Control","status":"TERMINATED","sponsor":"Sanofi","startDate":"2006-02","conditions":"Diabetes Mellitus, Type 2","enrollment":390},{"nctId":"NCT00135083","phase":"PHASE3","title":"Variable Bolus Regimen 1-2-3 for Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-08","conditions":"Diabetes Mellitus, Type 2","enrollment":347},{"nctId":"NCT00135096","phase":"PHASE3","title":"Insulin Glulisine Administered Pre-meal Versus Post-meal in Adult Subjects With Type 2 Diabetes Mellitus Receiving Insulin Glargine as Basal Insulin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-08","conditions":"Diabetes Mellitus, Type 2","enrollment":345},{"nctId":"NCT00310297","phase":"PHASE1","title":"Insulin Glulisine in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-11","conditions":"Type 2 Diabetes Mellitus","enrollment":""},{"nctId":"NCT00135057","phase":"PHASE3","title":"Insulin Glulisine in Adult Subjects With Type 2 Diabetes Receiving Insulin Glargine as Basal Insulin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-04","conditions":"Diabetes Mellitus, Type 2","enrollment":281},{"nctId":"NCT00290043","phase":"PHASE1","title":"Glulisine Pre- and Postmeal","status":"COMPLETED","sponsor":"Sanofi","startDate":"2001-12","conditions":"Diabetes Mellitus Type 1","enrollment":20},{"nctId":"NCT00526513","phase":"PHASE4","title":"Study of Safety and Effectiveness of Apidra® in Combination With Basal Insulin in Patients With Type 1 & 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-07","conditions":"Diabetes Mellitus","enrollment":188},{"nctId":"NCT01192711","phase":"PHASE3","title":"Insulin Administration Plus a Telemedicine System (Diabetes Interactive Diary - DID) vs Insulin Plus Common Practice","status":"UNKNOWN","sponsor":"Consorzio Mario Negri Sud","startDate":"2009-05","conditions":"Type 1 Diabetes","enrollment":130},{"nctId":"NCT00607087","phase":"PHASE4","title":"Effect of Insulin Glulisine Compared to Insulin Aspart and Insulin Lispro When Administered by Continuous Subcutaneous Insulin Infusion (CSII) on Specific Pump Parameters in Patient With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-01","conditions":"Diabetes Mellitus, Type 1","enrollment":289},{"nctId":"NCT01159353","phase":"PHASE1","title":"Pharmacodynamic and Pharmacokinetic Effects of Insulin Glulisine in Obese Subjects With Type 2 Diabetes After a Standard Meal in Comparison to Insulin Aspart","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-09","conditions":"Type 2 Diabetes Mellitus","enrollment":37},{"nctId":"NCT00640991","phase":"PHASE3","title":"REsearching Coronary REduction by Appropriately Targeting Euglycemia (RECREATE Pilot Study)","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2008-04","conditions":"Hyperglycemia, Cardiovascular Diseases, Myocardial Infarction","enrollment":500},{"nctId":"NCT01143948","phase":"PHASE4","title":"Various Insulin Regimens for Diabetic Inpatients With Cirrhosis Trial","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2011-01","conditions":"Type 2 Diabetes, Liver Cirrhosis","enrollment":45},{"nctId":"NCT00297583","phase":"PHASE1","title":"Insulin Glulisine in Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-04","conditions":"Type 1 Diabetes Mellitus","enrollment":""},{"nctId":"NCT00272064","phase":"PHASE3","title":"ELEONOR STUDY: Insulin Glulisine in Type 2 Diabetes Mellitus.","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-10","conditions":"Diabetes Mellitus, Type 2","enrollment":352},{"nctId":"NCT00271284","phase":"PHASE3","title":"Efficacy Study on the Control of Blood Glucose Concentration in Type 1 Diabetic Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-10","conditions":"Diabetes Mellitus, Type 1","enrollment":88},{"nctId":"NCT00311077","phase":"PHASE1","title":"Insulin Glulisine in Healthy Lean and Obese Subjects","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-04","conditions":"Diabetes Mellitus","enrollment":""}],"_emaApprovals":[],"_faersSignals":[{"count":4,"reaction":"HYPERKALAEMIA"},{"count":4,"reaction":"NAUSEA"},{"count":3,"reaction":"NODAL ARRHYTHMIA"},{"count":3,"reaction":"RENAL FAILURE"},{"count":3,"reaction":"WEIGHT DECREASED"},{"count":2,"reaction":"ABDOMINAL PAIN UPPER"},{"count":2,"reaction":"ASTHENIA"},{"count":2,"reaction":"ATRIAL SEPTAL DEFECT"},{"count":2,"reaction":"BUNDLE BRANCH BLOCK RIGHT"},{"count":2,"reaction":"CAESAREAN SECTION"}],"_approvalHistory":[],"publicationCount":211,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Apidra (insulin glulisine)","genericName":"Apidra (insulin glulisine)","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Insulin glulisine is a rapid-acting insulin analog that binds to insulin receptors on muscle and fat cells to promote glucose uptake and lower blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}